Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116405 | 0.87 | GNAO1 (0.41) | GNAO1GNAI3GNAI1DRD2KCNH2 | |
| SCHEMBL29244364 | 0.84 | GNAO1 (0.46) | GNAO1GNAI3GNAI1DRD2KCNH2 | |
| SCHEMBL7739859 | 0.83 | GNAO1 (0.45) | SLC18A3ALDH1A1KDM4EKMT2AGNAO1 | |
| SCHEMBL23828683 | 0.81 | GNAO1 (0.46) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL10076885 | 0.81 | DRD2 (0.47) | GNAO1GNAI3GNAI1DRD2KCNH2 | |
| SCHEMBL1316226 | 0.81 | SLC18A3 (0.47) | SLC18A3ALDH1A1KDM4EKMT2APKM | |
| SCHEMBL9939169 | 0.81 | SMN1; SMN2 (0.34) | GNAO1GNAI3GNAI1NCF1 | |
| SCHEMBL15223935 | 0.81 | HTR1A (0.43) | ALDH1A1KDM4EKMT2ALMNAHTT | |
| SCHEMBL28004439 | 0.79 | GNAI3 (0.46) | SLC18A3ALDH1A1KDM4EKMT2APKM | |
| SCHEMBL13827095 | 0.79 | GNAO1 (0.50) | SLC18A3ALDH1A1GNAO1GNAI3GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628044-B1 | PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-20230159573-A1 | SMALL MOLECULE STAT PROTEIN DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| WO-2023016567-A1 | METHODS OF TREATING A DISEASE OR DISORDER | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022261243-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220185831-A1 | STAT3 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-06-16 | — | — | US | disclosed |
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-06-07 | — | — | US | disclosed |
| WO-2022011205-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022011204-A1 | SMALL MOLECULE ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| WO-2012010704-A1 | NEW AMINOPYRAZOLOQUINAZOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-26 | — | — | WO | disclosed |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | US | disclosed |
| US-8017638-B2 | Isoxazole derivative and isothiazole derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1 | SHIONOGI & CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2010-08-12 | — | — | US | disclosed |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | SHIONOGI & CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | SLC18A3 3789/4885ALDH1A1 4361/4885KDM4E 2813/4885 |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | AR, GPER1, CRBN | SLC18A3 2749/4885ALDH1A1 291/4885KDM4E 3090/4885 |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | SLC18A3 4422/4885ALDH1A1 4410/4885KDM4E 2229/4885 |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | SLC18A3 2287/4885ALDH1A1 297/4885KDM4E 3351/4885 |
| US-20220185831-A1 | STAT3 PROTEIN DEGRADERS | STAT3, JAK2, STAT5A | SLC18A3 4854/4885ALDH1A1 1408/4885KDM4E 29/4885 |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | SLC18A3 3239/4885ALDH1A1 1744/4885KDM4E 3345/4885 |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | HSD3B1, NR5A1, HSD11B1 | SLC18A3 1973/4885ALDH1A1 203/4885KDM4E 2542/4885 |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | ESR2, IGF1R, ESRRA | SLC18A3 4500/4885ALDH1A1 2148/4885KDM4E 3910/4885 |
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | CDK4, CDK6, CDK2 | SLC18A3 4521/4885ALDH1A1 2112/4885KDM4E 1128/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | SLC18A3 4711/4885ALDH1A1 1168/4885KDM4E 2333/4885 |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | SLC18A3 3677/4885ALDH1A1 2827/4885KDM4E 3805/4885 |
| US-20230159573-A1 | SMALL MOLECULE STAT PROTEIN DEGRADERS | STAT1, STAT3, STAT5A | SLC18A3 4781/4885ALDH1A1 2054/4885KDM4E 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.